CU20220049A7 - Forma cristalina de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato, método para su preparación y composiciones farmacéuticas que la comprenden - Google Patents

Forma cristalina de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato, método para su preparación y composiciones farmacéuticas que la comprenden

Info

Publication number
CU20220049A7
CU20220049A7 CU2022000049A CU20220049A CU20220049A7 CU 20220049 A7 CU20220049 A7 CU 20220049A7 CU 2022000049 A CU2022000049 A CU 2022000049A CU 20220049 A CU20220049 A CU 20220049A CU 20220049 A7 CU20220049 A7 CU 20220049A7
Authority
CU
Cuba
Prior art keywords
quinazolin
methoxyphenyl
trifluoromethyl
fluoro
methoxy
Prior art date
Application number
CU2022000049A
Other languages
English (en)
Inventor
Helmut Buschmann
Bertran Jordi Carles Ceron
Thomas Goldner
Original Assignee
Aic246 Ag & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aic246 Ag & Co Kg filed Critical Aic246 Ag & Co Kg
Publication of CU20220049A7 publication Critical patent/CU20220049A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p><br /> La presente invención se refiere a una forma cristalina de trihidrato de sodio del ácido<br /> 2-[(4S)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4<em>H</em>-quinazolin-4-il]acético de formula I</p> <p>ESPACIO PARA FÓRMULA</p> <p>a un método eficaz para su preparación, así como a composiciones farmacéuticas que comprende a dicho compuesto.</p>
CU2022000049A 2020-02-27 2021-03-01 Forma cristalina de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato, método para su preparación y composiciones farmacéuticas que la comprenden CU20220049A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20159727 2020-02-27
PCT/EP2021/055045 WO2021170874A1 (en) 2020-02-27 2021-03-01 A method of producing a crystalline form of sodium 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate trihydrate

Publications (1)

Publication Number Publication Date
CU20220049A7 true CU20220049A7 (es) 2023-04-10

Family

ID=69742722

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2022000049A CU20220049A7 (es) 2020-02-27 2021-03-01 Forma cristalina de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato, método para su preparación y composiciones farmacéuticas que la comprenden

Country Status (19)

Country Link
US (1) US20230219899A1 (es)
EP (1) EP4110470A1 (es)
JP (1) JP2023519813A (es)
KR (1) KR20220148863A (es)
CN (1) CN115581118A (es)
AR (1) AR121439A1 (es)
AU (1) AU2021225363B2 (es)
BR (1) BR112022016929A2 (es)
CA (1) CA3169484A1 (es)
CL (1) CL2022002291A1 (es)
CO (1) CO2022012039A2 (es)
CU (1) CU20220049A7 (es)
EC (1) ECSP22066680A (es)
IL (1) IL295795A (es)
MX (1) MX2022010441A (es)
PE (1) PE20230515A1 (es)
TW (1) TW202140453A (es)
UY (1) UY39096A (es)
WO (1) WO2021170874A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE102012101659A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats

Also Published As

Publication number Publication date
CO2022012039A2 (es) 2022-11-18
EP4110470A1 (en) 2023-01-04
CN115581118A (zh) 2023-01-06
UY39096A (es) 2021-09-30
IL295795A (en) 2022-10-01
CA3169484A1 (en) 2021-09-02
KR20220148863A (ko) 2022-11-07
AR121439A1 (es) 2022-06-08
CL2022002291A1 (es) 2023-02-03
US20230219899A1 (en) 2023-07-13
MX2022010441A (es) 2022-10-18
TW202140453A (zh) 2021-11-01
WO2021170874A1 (en) 2021-09-02
PE20230515A1 (es) 2023-03-24
AU2021225363A1 (en) 2022-10-13
BR112022016929A2 (pt) 2022-12-06
AU2021225363B2 (en) 2024-09-19
ECSP22066680A (es) 2022-12-30
JP2023519813A (ja) 2023-05-15

Similar Documents

Publication Publication Date Title
RU2397976C2 (ru) Производные бензамидов и гетероаренов
UY37399A (es) Proceso químico para la elaboración de determinados derivados de pirimidina
EA201892300A1 (ru) Макроциклические ингибиторы mcl1 для лечения рака
PE20091099A1 (es) Derivados de aminobenzamida como agentes utiles para controlar parasitos animales
AR084639A1 (es) Formas polimorficas de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico y usos del mismo
CU24316B1 (es) Nuevos derivados fosfatos de 1,2,3,4-tetraisoquinolina amida fenilo, métodos de preparación de los mismos y composiciones farmacéuticas que los contienen
AR055622A1 (es) Metodos de preparacion de benzimidazoles sustituidos y compuestos derivados de los mismos.
CL2012001841A1 (es) Polimorfo cristalino de la forma a de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetato de sodio; método de preparación; composición farmacéutica; y su uso para el tratamiento o prevención de hiperuricemia o una enfermedad causada por niveles elevados de ácido úrico.
EA201001772A1 (ru) Производные 3,5-диамино-6-хлорпиразин-2-карбоновой кислоты и их применение в качестве блокаторов эпителиальных натриевых каналов для лечения заболеваний дыхательных путей
PE20160899A1 (es) Derivados de acido heteroaril butanoico como inhibidores de lta4h
DOP2014000286A (es) Compuestos de acido dimetil-benzoico
NZ714558A (en) Formulation comprising a hypolipidemic agent
MX2012002244A (es) Metodo para producir un solido cristalino de derivados de acido glicina-n, n-diacetico con higroscopicidad suficientemente reducida.
BRPI0608400B8 (pt) composto 2-(((4-((2,2-dimetil-1,3-dioxan-5-il)metóxi)-3,5-dimetilpiridin-2-il)metil)sulfinil)-1h-benzimidazol ou um sal de metal alcalino do mesmo
PE20220969A1 (es) Sal
CU20210007A7 (es) Derivados de aril-n-arilo para el tratamiento de una infección por virus de ácido ribonucleico (arn)
RS54523B1 (en) PROCEDURE FOR THE PREPARATION OF ESTERS (5-FLUORO-2-METHYL-3-HINOLIN-2-ILMETHYL-INDOL-1-IL) -CARCETIC ACIDS
PE20080175A1 (es) Sales de malato, y polimorfos de acido (3s,5s)-7-[3-amino-5-metil-piperidinil]-1-ciclopropil-1,4-dihidro-8-metoxi-4-oxo-3-quinolincarboxilico
CO6361848A2 (es) Composición para controlar enfermedades vegetales y metodo para controlar enfermedades vegetales
EA201270653A1 (ru) Антагонист dpи его применение
CU20220049A7 (es) Forma cristalina de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato, método para su preparación y composiciones farmacéuticas que la comprenden
WO2011037833A3 (en) Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
BRPI0814115B8 (pt) composição farmacêutica compreendendo o composto 11-deóxi-prostaglandina e método para estabilizar o composto
RU2009147291A (ru) Применение ингибиторов raf для лечения рака щитовидной железы
NO20084326L (no) Fremgangsmate for fremstilling av [(1R), 2S]-2-aminopropansyre 2-[4-(4-fluor-2-metyl-1H-indol-5-yloksy)-5-metylpyrrolo[2,1-f][1,2,4]triazin-6-yloksy]-1-metyletylester